Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
3,628
archived clinical trials in
Schizophrenia

CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
Status: Enrolling
Updated:  6/9/2014
Philadelphia VA Medical Center, Philadelphia, PA
mi
from
Philadelphia, PA
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
Status: Enrolling
Updated: 6/9/2014
Philadelphia VA Medical Center, Philadelphia, PA
mi
from
Philadelphia, PA
Click here to add this to my saved trials
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
Status: Enrolling
Updated:  6/9/2014
VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA
mi
from
Pittsburgh, PA
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
Status: Enrolling
Updated: 6/9/2014
VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
Status: Enrolling
Updated:  6/9/2014
Ralph H. Johnson VA Medical Center, Charleston, SC
mi
from
Charleston, SC
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
Status: Enrolling
Updated: 6/9/2014
Ralph H. Johnson VA Medical Center, Charleston, SC
mi
from
Charleston, SC
Click here to add this to my saved trials
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
Status: Enrolling
Updated:  6/9/2014
Michael E. DeBakey VA Medical Center, Houston, TX
mi
from
Houston, TX
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
Status: Enrolling
Updated: 6/9/2014
Michael E. DeBakey VA Medical Center, Houston, TX
mi
from
Houston, TX
Click here to add this to my saved trials
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
Status: Enrolling
Updated:  6/9/2014
Central Texas Veterans Health Care System Waco VA Medical Center, Waco, TX
mi
from
Waco, TX
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
Status: Enrolling
Updated: 6/9/2014
Central Texas Veterans Health Care System Waco VA Medical Center, Waco, TX
mi
from
Waco, TX
Click here to add this to my saved trials
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
Status: Enrolling
Updated:  6/9/2014
VA Puget Sound Health Care System American Lake Division, Tacoma, WA
mi
from
Tacoma, WA
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
Status: Enrolling
Updated: 6/9/2014
VA Puget Sound Health Care System American Lake Division, Tacoma, WA
mi
from
Tacoma, WA
Click here to add this to my saved trials
An Randomized Open-Label PK Study of LY03004 Compared to Risperdal® Consta® in Stable Patients With Schizophrenia or Schizoaffective Disorder
A Randomized, Open-Label Pharmacokinetic Study of LY03004 Compared to Risperdal® Consta® Following a Single Intramuscular Injection at 25 mg in Stable Patients With Schizophrenia and/or Schizoaffective Disorder
Status: Enrolling
Updated:  7/8/2014
Neuropsychiatric Research Center of Orange County
mi
from
Orange County, CA
An Randomized Open-Label PK Study of LY03004 Compared to Risperdal® Consta® in Stable Patients With Schizophrenia or Schizoaffective Disorder
A Randomized, Open-Label Pharmacokinetic Study of LY03004 Compared to Risperdal® Consta® Following a Single Intramuscular Injection at 25 mg in Stable Patients With Schizophrenia and/or Schizoaffective Disorder
Status: Enrolling
Updated: 7/8/2014
Neuropsychiatric Research Center of Orange County
mi
from
Orange County, CA
Click here to add this to my saved trials
An Randomized Open-Label PK Study of LY03004 Compared to Risperdal® Consta® in Stable Patients With Schizophrenia or Schizoaffective Disorder
A Randomized, Open-Label Pharmacokinetic Study of LY03004 Compared to Risperdal® Consta® Following a Single Intramuscular Injection at 25 mg in Stable Patients With Schizophrenia and/or Schizoaffective Disorder
Status: Enrolling
Updated:  7/8/2014
Community Clinical Research
mi
from
Austin, TX
An Randomized Open-Label PK Study of LY03004 Compared to Risperdal® Consta® in Stable Patients With Schizophrenia or Schizoaffective Disorder
A Randomized, Open-Label Pharmacokinetic Study of LY03004 Compared to Risperdal® Consta® Following a Single Intramuscular Injection at 25 mg in Stable Patients With Schizophrenia and/or Schizoaffective Disorder
Status: Enrolling
Updated: 7/8/2014
Community Clinical Research
mi
from
Austin, TX
Click here to add this to my saved trials
Safety and Tolerability of Multiple Doses of ITI-214 in Healthy Adults and in Adults With Stable Schizophrenia
A Phase 1, Randomized, Placebo- Controlled, Double-Blind Safety, Tolerability, Pharmacokinetic, and Exploratory Pharmacodynamic Study in Healthy Subjects and Subjects With Stable Schizophrenia After Multiple Doses of ITI-214
Status: Enrolling
Updated:  7/28/2014
Clinical Research Facility
mi
from
Glendale, CA
Safety and Tolerability of Multiple Doses of ITI-214 in Healthy Adults and in Adults With Stable Schizophrenia
A Phase 1, Randomized, Placebo- Controlled, Double-Blind Safety, Tolerability, Pharmacokinetic, and Exploratory Pharmacodynamic Study in Healthy Subjects and Subjects With Stable Schizophrenia After Multiple Doses of ITI-214
Status: Enrolling
Updated: 7/28/2014
Clinical Research Facility
mi
from
Glendale, CA
Click here to add this to my saved trials
Safety and Tolerability of Multiple Doses of ITI-214 in Healthy Adults and in Adults With Stable Schizophrenia
A Phase 1, Randomized, Placebo- Controlled, Double-Blind Safety, Tolerability, Pharmacokinetic, and Exploratory Pharmacodynamic Study in Healthy Subjects and Subjects With Stable Schizophrenia After Multiple Doses of ITI-214
Status: Enrolling
Updated:  7/28/2014
Clinical Research Facility
mi
from
New York, NY
Safety and Tolerability of Multiple Doses of ITI-214 in Healthy Adults and in Adults With Stable Schizophrenia
A Phase 1, Randomized, Placebo- Controlled, Double-Blind Safety, Tolerability, Pharmacokinetic, and Exploratory Pharmacodynamic Study in Healthy Subjects and Subjects With Stable Schizophrenia After Multiple Doses of ITI-214
Status: Enrolling
Updated: 7/28/2014
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
mi
from
Birmingham, AL
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
mi
from
Little Rock, AR
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
mi
from
Little Rock, AR
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
mi
from
Cerritos, CA
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
mi
from
Cerritos, CA
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
mi
from
Culver City, CA
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
mi
from
Culver City, CA
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
mi
from
Escondido, CA
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
mi
from
Escondido, CA
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
mi
from
Garden Grove, CA
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
mi
from
Garden Grove, CA
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
mi
from
Oakland, CA
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
mi
from
Oakland, CA
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
mi
from
Oceanside, CA
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
mi
from
Oceanside, CA
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
mi
from
Orange, CA
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
mi
from
Orange, CA
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
mi
from
Riverside, CA
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
mi
from
Riverside, CA
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
mi
from
San Diego, CA
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
mi
from
San Diego, CA
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
mi
from
San Diego, CA
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
mi
from
San Diego, CA
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
mi
from
Torrance, CA
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
mi
from
Torrance, CA
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
mi
from
Hartford, CT
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
mi
from
Hartford, CT
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
mi
from
New Haven, CT
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
mi
from
New Haven, CT
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
mi
from
Washington,
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
mi
from
Washington,
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
mi
from
Bradenton, FL
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
mi
from
Bradenton, FL
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
mi
from
Lauderhill, FL
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
mi
from
Lauderhill, FL
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
mi
from
Sanford, FL
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
mi
from
Sanford, FL
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
mi
from
Atlanta, GA
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
mi
from
Atlanta, GA
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
mi
from
Hoffman Estates, IL
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
mi
from
Hoffman Estates, IL
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
mi
from
Schaumburg, IL
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
mi
from
Schaumburg, IL
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
mi
from
Lake Charles, LA
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
mi
from
Lake Charles, LA
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
mi
from
Shreveport, LA
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
mi
from
Shreveport, LA
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
mi
from
Rockville, MD
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
mi
from
Rockville, MD
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
mi
from
O'Fallon, MO
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
mi
from
O'Fallon, MO
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
mi
from
St. Louis, MO
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
mi
from
St. Louis, MO
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
mi
from
Las Vegas, NV
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
mi
from
Las Vegas, NV
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
mi
from
Jamaica, NY
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
mi
from
Jamaica, NY
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
mi
from
New York, NY
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
mi
from
New York, NY
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
mi
from
Dayton, OH
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
mi
from
Dayton, OH
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
mi
from
Oklahoma City, OK
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
mi
from
Memphis, TN
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
mi
from
Memphis, TN
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
mi
from
Austin, TX
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
mi
from
Austin, TX
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
mi
from
Austin, TX
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
mi
from
Austin, TX
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
mi
from
Dallas, TX
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
mi
from
Dallas, TX
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
mi
from
Dallas, TX
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
mi
from
Dallas, TX
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
mi
from
DeSoto, TX
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
mi
from
DeSoto, TX
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
mi
from
Houston, TX
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated:  8/11/2014
Pfizer Investigational Site
mi
from
Salt Lake City, UT
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
A 12-Week, Randomized, Phase 2, Double-Blind, Parallel-Group Study Of Two Dose Levels Of PF-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-Optimally Controlled Symptoms Of Schizophrenia
Status: Enrolling
Updated: 8/11/2014
Pfizer Investigational Site
mi
from
Salt Lake City, UT
Click here to add this to my saved trials